ATE333885T1 - Verwendung von sulodexid zur behandlung von reizdarm - Google Patents

Verwendung von sulodexid zur behandlung von reizdarm

Info

Publication number
ATE333885T1
ATE333885T1 AT02733192T AT02733192T ATE333885T1 AT E333885 T1 ATE333885 T1 AT E333885T1 AT 02733192 T AT02733192 T AT 02733192T AT 02733192 T AT02733192 T AT 02733192T AT E333885 T1 ATE333885 T1 AT E333885T1
Authority
AT
Austria
Prior art keywords
composition
sulodexide
clathrate
solvate
hydrate
Prior art date
Application number
AT02733192T
Other languages
English (en)
Inventor
Michael Spero
Noa Shelach
Morris Laster
Original Assignee
Keryx Biopharmceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Keryx Biopharmceuticals Inc filed Critical Keryx Biopharmceuticals Inc
Application granted granted Critical
Publication of ATE333885T1 publication Critical patent/ATE333885T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
AT02733192T 2001-05-17 2002-05-19 Verwendung von sulodexid zur behandlung von reizdarm ATE333885T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29166701P 2001-05-17 2001-05-17

Publications (1)

Publication Number Publication Date
ATE333885T1 true ATE333885T1 (de) 2006-08-15

Family

ID=23121293

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02733192T ATE333885T1 (de) 2001-05-17 2002-05-19 Verwendung von sulodexid zur behandlung von reizdarm

Country Status (12)

Country Link
US (1) US20030008844A1 (de)
EP (1) EP1392329B1 (de)
JP (1) JP2004534087A (de)
AT (1) ATE333885T1 (de)
AU (1) AU2002304265B2 (de)
CA (1) CA2447280A1 (de)
DE (1) DE60213404T2 (de)
DK (1) DK1392329T3 (de)
IL (1) IL158903A0 (de)
MX (1) MXPA03010493A (de)
NZ (1) NZ530020A (de)
WO (1) WO2003002129A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL150907A (en) * 2002-07-25 2007-07-04 Stephan Cherkez Process for the preparation of stable amorphous calcium pseudomonate
US20040220153A1 (en) * 2002-09-24 2004-11-04 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
MY162179A (en) * 2004-04-01 2017-05-31 Elan Pharm Inc Steroid sparing agents and methods of using same
JP2006117569A (ja) * 2004-10-20 2006-05-11 Juntendo ステロイド依存性あるいはステロイド抵抗性潰瘍性大腸炎治療薬
FR2884422B1 (fr) * 2005-04-18 2008-04-11 Roquette Freres Composition anti-inflammatoire de l'intestin comprenant des maltodextrines branchees
US20080081067A1 (en) * 2006-10-03 2008-04-03 Gupta Manishkumar Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
EP2361242B1 (de) 2008-10-17 2018-08-01 Oryzon Genomics, S.A. Oxidaseinhibitoren und deren verwendung
US8993808B2 (en) 2009-01-21 2015-03-31 Oryzon Genomics, S.A. Phenylcyclopropylamine derivatives and their medical use
EP2480528B1 (de) 2009-09-25 2018-08-29 Oryzon Genomics, S.A. Lysinspezifische demethylase-1-inhibitoren und ihre verwendung
US8946296B2 (en) 2009-10-09 2015-02-03 Oryzon Genomics S.A. Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use
WO2011106573A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae
US9616058B2 (en) 2010-02-24 2017-04-11 Oryzon Genomics, S.A. Potent selective LSD1 inhibitors and dual LSD1/MAO-B inhibitors for antiviral use
EP2547208B1 (de) * 2010-03-17 2016-07-27 Troy Technology II, Inc. Formulierung mit biozidleistung
MX2012012111A (es) 2010-04-19 2013-05-30 Oryzon Genomics Sa Inhibidores de demetilasa-1 especifica de lisina y su uso.
JP6054868B2 (ja) 2010-07-29 2016-12-27 オリゾン・ジェノミックス・ソシエダッド・アノニマＯｒｙｚｏｎ Ｇｅｎｏｍｉｃｓ Ｓ．Ａ． Ｌｓｄ１のアリールシクロプロピルアミンをベースとしたデメチラーゼ阻害剤およびそれらの医学的使用
WO2012013727A1 (en) 2010-07-29 2012-02-02 Oryzon Genomics S.A. Cyclopropylamine derivatives useful as lsd1 inhibitors
WO2012045883A1 (en) 2010-10-08 2012-04-12 Oryzon Genomics S.A. Cyclopropylamine inhibitors of oxidases
WO2012072713A2 (en) 2010-11-30 2012-06-07 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
EP2712315B1 (de) 2011-02-08 2021-11-24 Oryzon Genomics, S.A. Lysindemethylase-hemmer für myeloproliferative erkrankungen
EP2741741A2 (de) * 2011-05-19 2014-06-18 Oryzon Genomics, S.A. Lysindemethylaseinhibitoren zur entzündungserkrankungen oder -zustände
DK2543357T3 (en) * 2011-07-07 2018-07-02 Holy Stone Healthcare Co Ltd COMPOSITION FOR USE FOR TREATMENT AND PREVENTION OF INFLAMMATION-RELATED DISORDERS
US9469597B2 (en) 2011-10-20 2016-10-18 Oryzon Genomics S.A. (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
CN104203914B (zh) 2011-10-20 2017-07-11 奥瑞泽恩基因组学股份有限公司 作为lsd1抑制剂的(杂)芳基环丙胺化合物
EP2857020A4 (de) * 2012-06-05 2015-10-28 Yutoku Pharmaceutical Ind Co Ltd Mirtazapinhaltiges, transdermal absorbierbares, hautadhäsives präparat
GB201211982D0 (en) * 2012-07-05 2012-08-22 Isis Innovation Biomarker
CN104017102B (zh) * 2014-06-19 2016-02-24 深圳市海普瑞药业股份有限公司 乙醇沉淀法从肝素副产物制备舒洛地特原料的方法
US9668991B1 (en) 2015-12-09 2017-06-06 International Business Machines Corporation SCFA colonic composition
CN108354943A (zh) * 2018-02-13 2018-08-03 南方医科大学南方医院 新生霉素用于制备抑制trpv1表达和转运功能的药物的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2426586A1 (de) * 1973-06-14 1975-01-09 Opocrin Srl Verfahren zur herstellung von glukuronil-glukosamin-glykan-sulfaten mit antilipaemischer wirkung
IT1274351B (it) * 1994-10-06 1997-07-17 Alfa Wassermann Spa Uso di alcuni glicosaminoglicani nella dialisi peritoneale.
GB0003048D0 (en) * 2000-02-11 2000-03-29 Dealler Stephen F The therapeutic use of polysulphonated polyglycosides or other polyanionic compounds in autism

Also Published As

Publication number Publication date
MXPA03010493A (es) 2005-06-06
AU2002304265B2 (en) 2008-04-10
DE60213404T2 (de) 2007-08-30
JP2004534087A (ja) 2004-11-11
WO2003002129A1 (en) 2003-01-09
US20030008844A1 (en) 2003-01-09
IL158903A0 (en) 2004-05-12
EP1392329B1 (de) 2006-07-26
EP1392329A1 (de) 2004-03-03
NZ530020A (en) 2005-08-26
DE60213404D1 (de) 2006-09-07
WO2003002129B1 (en) 2003-08-14
DK1392329T3 (da) 2006-11-27
CA2447280A1 (en) 2003-01-09

Similar Documents

Publication Publication Date Title
ATE333885T1 (de) Verwendung von sulodexid zur behandlung von reizdarm
WO2001042231A3 (en) Polyhydroxystilbenes and stilbene oxides as antisoriatic agents and protein kinase inhibitors
UY27438A1 (es) Composición farmaceútica que comprende un conjugado oligómero-farmaco insulina, método para tratar deficiencia de insulina en un sujeto, método para proveer una composición farmacéutica.
BR0110420A (pt) Agonistas muscarìnicos
ATE375341T1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
ATE396973T1 (de) Benzylether- und benzylamino-beta-sekretase- hemmer zur behandlung von alzheimer-krankheit
BR0013897A (pt) Uso de ácido linoleico conjugado (cla) ou de um seu derivado, composição tópica cosmética ou dermatológica, e, método de tratamento e/ou de profilaxia de celulite e de depósitos de gordura
BR0211119A (pt) Composto, método de tratar um paciente que tenha, ou de prevenir um paciente de pegar, uma doença ou condição, uso de um composto, e, método para fabricar um composto
ATE427925T1 (de) Phenoxycarbonsaureverbindungen und zusammensetzungen zur verabreichung aktiver wirkstoffe
DE69930259D1 (de) Zusammensetzungen zur anwendung von entzündungshemmenden, insbesondere antiseptischen und/oder wundheilenden wirkstoffen im oberen atemwegtrakt und/oder ohr
BRPI0113042B8 (pt) composto da fórmula ou um seu solvato fisiologicamente aceitável, uso do mesmo, composição farmacêutica, formulação farmacêutica, método para o tratamento de um indivíduo humano ou animal com uma condição inflamatória e/ou alérgica, e, processo para preparar um composto ou um seu solvato
NO20050851L (no) Kaspase-inhibitorer og anvendelser derav
ATE320803T1 (de) Verfahren zur behandlung von alzheimerschen krankheit
MXPA05011203A (es) Fenacil-2-hidroxi-3-diaminoalcanos.
ATE415410T1 (de) Pharmazeutische zusammensetzung zur behandlung von psoriasis und anderen hautkrankheiten
ATE412646T1 (de) Zur behandlung von schmerzen geeignete therapeutische mittel
ATE451123T1 (de) Vaginal verabreichbare zusammensetzung zur behandlung von uteriner dysrhythmie
ATE422357T1 (de) Verwendung von allopurinol zur behandlung von bluthochdruck
IS6558A (is) Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni
DE69932939D1 (de) Fulvinsäure und dessen verwendung zur behandlung von diversen krankheitszuständen
ATE358474T1 (de) Halogenhaltige zusammensetzung, verfahren zu deren herstellung und deren verwendung
EP1348466A3 (de) Schmerzbehandlung mit Adenosin-Tetraphosphaten
DE60210614D1 (de) Für die behandlung von alzheimer krankheit geeignete makrocyclen
MXPA03011521A (es) Aminadioles para tratamiento de enfermedad de alzheimer.
DE69407787D1 (de) Mischungen zur desodorisierung von tierexcrementen und entsprechendes verfahren zur desodorisierung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties